https://www.cruk.cam.ac.uk/publications/response-and-resistance-to-bet-bromodomain-inhibitors-in-triplenegative-breast-cancer/
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. - Cancer...
Authors: S Shu, CY Lin, HH He, RM Witwicki, DP Tabassum, JM Roberts, M Janiszewska, SJ Huh, Y Liang, J Ryan, E Doherty, H Mohammed, H Guo, DG Stover, MB Ekram,...
bromodomain inhibitors
https://pubchem.ncbi.nlm.nih.gov/bioassay/1796005
AID 1796005 - BROMOscan Binding Assay from US Patent US10124009: "Bromodomain inhibitors" - PubChem
BioAssay record AID 1796005 submitted by BindingDB: BROMOscan Binding Assay from US Patent US10124009:
from us
https://anesthesiology.weill.cornell.edu/publications/crystal-structure-of-124triazolo43-bpyridazine-derivatives-as-brd4-bromodomain
Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors...
https://conservancy.umn.edu/items/b9d44028-403d-4d50-8808-653c5f8f5043
Development and Cellular Evaluation of Selective N-Terminal BET Bromodomain Inhibitors
As regulators of transcription, proteins that interpret post-translational modifications to N-terminal histone tails are essential for maintaining cellular...
cellular evaluationdevelopment
https://pubmed.ncbi.nlm.nih.gov/22437115/
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of...
A novel series of quinoline isoxazole BET family bromodomain inhibitors are discussed. Crystallography is used to illustrate binding modes and rationalize...